Short answer: AC-262 (AC-262536, sold as “Accadrine”) is an experimental SARM that has only been tested in cells and in rats. In castrated male rats, two weeks of AC-262 grew a hormone-sensitive muscle (the levator ani) and lowered raised LH levels, with weak effects on the prostate (Piu 2008). It has never been tested in people, so there is no researched dosage, and its side effects in humans are not established.

AC-262 at a glance

Question What is known Evidence
What it is Nonsteroidal SARM discovered by ACADIA Pharmaceuticals; a partial agonist of the androgen receptor Cell study
Muscle Levator ani muscle grew in castrated rats over 2 weeks Animal
Prostate Weak effect on prostate and seminal vesicle weight compared with testosterone Animal
Hormones Lowered the raised LH of castrated rats, a sign it can suppress natural testosterone signaling Animal
Human trials None published None
Half-life, dose, side effects in people Not established None

All the findings above come from one paper (Piu 2008). The full compound page is our AC-262536 review, and the SARMs database shows how much human evidence other compounds have by comparison.

What is AC-262?

AC-262, also written AC262 or AC-262536 and sold as “Accadrine”, is a nonsteroidal selective androgen receptor modulator. It was identified by ACADIA Pharmaceuticals with a cell-based screening test as a potent, selective androgen-receptor ligand with partial agonist activity relative to testosterone (Piu 2008).

Earlier versions of this article said it was first made to treat Alzheimer’s disease, went through clinical trials in patients and is free of the risks of steroids. We found no evidence for any of that: the published research is the 2008 rat and cell study, and no clinical trial has been reported.

How does AC-262 work?

Like other SARMs, AC-262 binds the androgen receptor and switches it on. As a partial agonist, it activated the receptor less fully than testosterone in cell tests. In castrated rats this produced a muscle response with much less growth of the prostate and seminal vesicles than testosterone (Piu 2008).

Claims that it works “within minutes”, gives fixed percentages of testosterone’s anabolic and androgenic effect in people, or cannot affect hormones in women have no human data behind them. In the rat study it lowered LH, which means it does act on the hormone system.

AC-262 Benefits

What has been shown, and where:

  • Muscle (animal): anabolic parameters improved in castrated rats over 2 weeks, mainly growth of the levator ani muscle (Piu 2008).
  • Lower androgenic effect (animal): weak effects on prostate and seminal vesicle weight compared with testosterone (Piu 2008).
  • Fat loss and metabolic rate: not studied.
  • Prostate cancer prevention: not studied; this claim from the earlier version of this page had no source.
  • Alzheimer’s or memory: not studied for AC-262.

AC262 Dosage Guidelines

There is no researched AC-262 dosage: it has never been given to people in a study, and rat doses cannot be converted into human doses. Products are commonly sold as 10 mg capsules, and users commonly report 10–30 mg a day for about 4–8 weeks. That range is anecdotal, not a tested or safe dose.

  • Half-life: not established in humans, so once- versus twice-daily dosing has no basis in data.
  • PCT: because AC-262 lowered LH in rats, suppression of natural testosterone is plausible; it has not been measured in people. Bloodwork before and after is the only way to know; see the PCT and bloodwork planner.
  • Women: there are no data in women.

Bulking and Cutting Stacks

No AC-262 stack has been studied. Users describe pairing it with other SARMs for bulking or with cardarine for cutting, but every partner compound adds its own risks; check the combination with the stack checker. Reports of an “energy rush within 12 minutes” are anecdotal.

AC-262 Side Effects

Side effects of AC-262 in people have not been studied. Users report nausea, raised blood pressure, skin rashes, fatigue and vision changes; these are anecdotal reports that no study has checked. The earlier claim that prostate enlargement, testicle shrinkage and gynecomastia are “not possible” on AC-262 was not supported and has been removed.

What is known from related compounds: SARMs as a class lower testosterone and HDL cholesterol in human trials, and liver injury is the most common serious harm reported in healthy adults using them (Vignali 2023). Products sold as SARMs are often mislabeled; in one test only 52% contained a SARM at all (Van Wagoner 2017). AC-262 is not named on the WADA list, but WADA bans SARMs as a class and “other anabolic agents” at all times (WADA 2026).

AC-262 VS Ostarine

Ostarine (MK-2866, enobosarm) is the most studied SARM: it has been through Phase 2 and Phase 3 trials in more than 1,000 people. AC-262 has only been tested in rats. That difference in evidence is the most important one between them.

A Brief Rundown of Comparison

AC-262 Ostarine
Human trials None Several Phase 2 and two Phase 3 trials
Muscle Rat levator ani muscle grew in 2 weeks About +1.3 kg lean mass vs placebo on 3 mg/day for 86 days in older adults (Dalton 2011)
Testosterone LH lowered in castrated rats Total testosterone down about 6–7 nmol/L in older men on 1–3 mg/day
Cholesterol Not studied HDL down 17–27%
Liver Not studied ALT rises in trials; cholestatic liver injury case reports
Half-life Not established About 14–24 hours

The earlier version of this page said ostarine causes prostate enlargement and that AC-262 shrinks the prostate in people; neither is supported. For more on ostarine, see the ostarine fact sheet.

Conclusion

AC-262 has one published study behind it: a 2008 paper showing a muscle response with weak prostate effects and lower LH in castrated rats. There are no human trials, no researched dose and no human safety data. Treat the benefits and the 10–30 mg doses you will see online as claims, not findings, and compare it with better-studied options in the database or our AC-262536 review.

Frequently asked questions

What is AC-262?

An experimental SARMEvidence: Animal

AC-262 (AC-262536, sold as Accadrine) is a nonsteroidal SARM identified by ACADIA Pharmaceuticals, a partial agonist of the androgen receptor. It has only been tested in cells and rats.

Read the full section

What is the AC-262 dosage?

No researched doseEvidence: User reports

AC-262 has never been tested in people, and rat doses cannot be converted into human doses. The 10–30 mg a day users report is anecdotal, not a tested or safe dose.

Read the full section

What are the side effects of AC-262?

Not established in humansEvidence: User reports

Users report nausea, raised blood pressure, rashes, fatigue and vision changes, but no study has checked these. In rats it lowered LH, so suppression of natural testosterone is plausible.

Read the full section

Does AC-262 need PCT?

UnknownEvidence: Animal

It lowered LH in castrated rats, which suggests it can suppress the testosterone axis, but this has not been measured in people. Bloodwork before and after is the only way to know.

Read the full section

Is AC-262 better than ostarine?

No head-to-head dataEvidence: Trial

Ostarine has Phase 2 and 3 trials in over 1,000 people, with about 1.3 kg lean mass gained and lower HDL and testosterone. AC-262 has only rat data.

Read the full section

Is AC-262 banned in sport?

Yes, as a SARMEvidence: Law

AC-262 is not named on the WADA list, but WADA bans SARMs as a class and other anabolic agents at all times.

Read the full section

Sources

  1. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator 2008 · PMID 18164613
  2. PubChem: AC-262536 (CID 44512434), names and synonyms 2026
  3. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847
  4. Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users 2023 · PMID 37218811
  5. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet 2017 · PMID 29183075
  6. WADA: The Prohibited List (2026 List, in force from 1 January 2026) 2026